Rhabdomyosarcoma: Evaluation of IRS III Protocol used in Cancer Hospital (INCA) Rio de Janeiro 1988-1993
DOI:
https://doi.org/10.32635/2176-9745.RBC.1997v43n4.2864Keywords:
Rhabdomyosarcoma, Childhood Sarcomas, Survival, Malformations and CancerAbstract
Thirty nine Rhabdomyosarcoma patients aged 0-21 years were studied. They were registered at the in Hospital between January 1988 and December 1993. Their treatment, stage, histologic groups and distribution by primary site were based on IRS 111 (Intergroup Rhabdomyosarcoma Study) protocol. Survival curves were plotted for two differents groups. The first one included all patients. The initial moment was the begining of the therapy, and the final event the last observation date. For the second group, the initial moment was the end of therapy for those in complete remission and the final event was the last observation or relapse of the disease. The method used was the Kaplan - Meier Survival Tables. Toxicity was moderate and there was no fatal toxicity. The seven-year survival rate was 49,2% for the first group, with the median follow-up of29 months. The survival for rate the second group, with 21 patients, was 78% in six years, with median follow-up of 32 months. The proportion of patients with advanced disease (92%) was high, and we conclude that the results are similar to those reported by the International literature and therapeutic regimens are safe.
Downloads
References
Raney, R.B.; Hays, D.M.; Tefft, M. et al; - Rhabdomyosarcoma and Undiferentiated Sarcoma, in Pizzo PA, Poplack DG (eds): Principies and Practice of Pediatric Oncology. Philadelphia, VA, Lippincott, 769-794, 1993.
Crist, W.; Gehan, E.; Ragab, A.H. et al - The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13: 610-630, 1995. DOI: https://doi.org/10.1200/JCO.1995.13.3.610
Wilbur, J.R. - Combination chemotherapy for Embrional Rhabdomyosarcoma. Cancer Chemother Rep 58: 281-284, 1974.
Maurer, H.M.; Raney, R.B.; Jones, P.M. et al. - Intergroup Rhabdomyosarcoma Study-III by Children’ s Cancer Study Group, Pediatric Oncology Group and United Kingdom Children’s Cancer Study Group. Protocolo original, 1984.
Horowitz, M.E.; Etcubanas, E.; Christensen, M.L. et al. - Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcomaa: A model for anticancer drug development. y Clín Oncol 6: 308-314, 1988. DOI: https://doi.org/10.1200/JCO.1988.6.2.308
Maurer, H.M.; Gehan, E.; Beltangady, M. et al. - The Intergroup Rhabdomyosarcoma Study- I: A final report. Cancer 61: 209-220, 1988. DOI: https://doi.org/10.1002/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L
Maurer, H.M., Gehan, E.; Beltangady, M. et al. - The Intergroup Rhabdomyosarcoma Study-II. Cancer 77; 1904-1922, 1993. DOI: https://doi.org/10.1002/1097-0142(19930301)71:5<1904::AID-CNCR2820710530>3.0.CO;2-X
Kleinbaum, D.G. - Survival Analysis Module Series, Part I: Introduction to Survival Analysis, 1989.
Kleinbaum, D.G. - Survival Analysis Module Series, Part II: Kaplan & Meier Survival Curves and other Graphical Methods, 1993.